Presents Wegovy post hoc analyses at ADA Scientific Sessions
- Post hoc analyses from SELECT, STEP, ESSENCE, and OASIS 4 explored semaglutide across obstructive sleep apnea, asthma-related adverse outcomes, blood pressure, liver health, cardiometabolic risk factors, and other obesity-related complications.
- SELECT post hoc analyses found semaglutide 2.4 mg was associated with lower incidence of obstructive sleep apnea and lower asthma-related adverse outcomes versus placebo.
- In pooled STEP trial data, semaglutide 2.4 mg was associated with improvements in systolic and diastolic blood pressure versus placebo from baseline to week 68.
- In ESSENCE part 1 and STEP 1, semaglutide 2.4 mg was associated with improvements in cardiometabolic and liver health parameters, including fatty liver index scores.
- OASIS 4 post hoc analysis found semaglutide tablets 25 mg had similar or greater cardiometabolic improvements in overweight/obesity class I versus obesity class II/III at week 64.